Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.

@article{Sibaud2018DermatologicRT,
  title={Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.},
  author={Vincent Sibaud},
  journal={American journal of clinical dermatology},
  year={2018},
  volume={19 3},
  pages={
          345-361
        }
}
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1)] represents a major breakthrough in cancer therapy. Although they present a favorable risk/benefit ratio, immune checkpoint blockade therapies have a very specific safety profile. Due to their unique mechanism of action, they entail a new spectrum of adverse events that are mostly immune… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
2 Citations
109 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 109 references

Similar Papers

Loading similar papers…